Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Clinical trial NCT06360042 · RECRUITING
Trial details
- NCT number
- NCT06360042
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2027-03-31
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.